ADAM17 and cholestasis: In our current study, we now show that inhibition of ADAM17 ameliorates cholestasis-associated sickness behavior development, as reflected by an increase in time spent engaging in social interaction and a decrease in time spent remaining immobile in DPC 333-treated cholestatic mice.